ArticleScience translational medicine2023
SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
12.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 48 citations in OpenAlex.
- Encapsulation of Exosomal Volatile Organic Compounds for Modulating the NF-κB Pathway in Monocytes.ACS bio & med chem Au · 2026Article
- Review
- Evidence for early endothelial dysfunction associated with the ALDH2 rs671 gene variant: A preliminary investigation with young East Asians.Experimental physiology · 2026Article
- Vascularized Cardiac Tissue Engineering: From Advances in Biofabrication to Translational Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Vasculoprotective Effects of Sodium-Glucose Co-Transporter Inhibitors in Non-Diabetic Experimental Settings: A Narrative Review.International journal of molecular sciences · 2026Review
- Integrative Genomics Reveals Causal Pleiotropy and Therapeutic Opportunities at the Interface of Acute Pancreatitis and Infection.Journal of hepato-biliary-pancreatic sciences · 2026Article
- ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury.Circulation · 2026Article
- Article
- NHE1 in macrophages promotes octanal/Olfr2-induced atherosclerosis via calcium-dependent ROS and NLRP3 inflammasome activation.Scientific reports · 2025Article
- The Impact of Sodium Glucose Co-Transporter 2 (SGLT-2) Inhibitors on Atherogenesis: A Systematic Review of Experimental and Clinical Evidence.Life (Basel, Switzerland) · 2025Review
- Early cardioprotective effects of SGLT2i on hypertensive cardiac remodeling via STIM1/Orai1-dependent calcium signaling: beyond blood pressure control.Journal of bioenergetics and biomembranes · 2025Article
- Targeting USP21 to inhibit abdominal aortic aneurysm progression by suppressing the phenotypic transition of vascular smooth muscle cells.Cell reports. Medicine · 2025Article
- ALDH2 Enzyme Deficiency in Diabetic Cardiomyopathy.International journal of molecular sciences · 2025Review
- The Role of Mitophagy in Cardiac Metabolic Remodeling of Heart Failure: Insights of Molecular Mechanisms and Therapeutic Prospects.Journal of cardiovascular translational research · 2025Review
- Empagliflozin Reduces High Glucose-Induced Cardiomyopathy in hiPSC-Derived Cardiomyocytes : Glucose-induced Lipotoxicity in hiPSC-Derived Cardiomyocytes.Stem cell reviews and reports · 2025Article
- Single nucleotide polymorphisms: Implications in the early diagnosis and targeted intervention of coronary microvascular dysfunction.Genes & diseases · 2025Review
- Beyond ketosis: the search for the mechanism underlying SGLT2-inhibitor benefit continues.The Journal of clinical investigation · 2024Article
- ALDH2 mediates the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on improving cardiac remodeling.Cardiovascular diabetology · 2024Article
- Clinical trials in-a-dish for cardiovascular medicine.European heart journal · 2024Review
- Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.Basic research in cardiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 1 country.
Hongchao GuoStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-8884-7358
Xuan YuDepartment of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Yu LiuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-7110-127X
David T PaikStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-7830-312X
Johanne Marie JustesenBiomedical Data Science, Stanford University School of Medicine, Stanford, CA 94305, USA.
Mark ChandyStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-6741-2822
James W S JahngStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-2367-6567
Tiejun ZhangStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Weijun WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Freeborn RwereDepartment of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-7037-6850
Shane Rui ZhaoStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-2137-5536
Suman PokhrelDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-2258-8768
Rabindra V ShivnaraineGreenstone Biosciences, 3160 Porter Drive, Palo Alto, CA 94305, USA.
Souhrid MukherjeeGreenstone Biosciences, 3160 Porter Drive, Palo Alto, CA 94305, USA.ORCID 0000-0002-8355-3000
Daniel J SimonDepartment of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Amit ManhasStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-6044-4576
Angela ZhangStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-0906-6770
Che-Hong ChenDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-0765-0893
Manuel A RivasBiomedical Data Science, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-1457-9925
Eric R GrossStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-0589-6446
Daria Mochly-RosenDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-6691-8733
Joseph C WuStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-6068-8041
Cardiovascular Institute of the South · USStanford University · USSystem Biosciences (United States) · US
Funding
Project 3 (Mercola)P01HL141084 · NHLBI · STANFORD UNIVERSITY · PI Joseph C. Wu · 2019 to 2026
$21.1MMECHANISMS OF ETHANOL-INDUCED CARDIAC PROTECTIONR01AA011147 · NIAAA · STANFORD UNIVERSITY · PI DARIA MOCHLY-ROSEN · 1996 to 2026
$8.2MElucidating Mechanism of Cardiac Fibrosis with Cell Village of Pooled Human iPSCsR01HL130020 · NHLBI · STANFORD UNIVERSITY · PI Ronglih Liao, MARK MERCOLA · 2016 to 2026
$7.3MHuman Induced Pluripotent Stem Cells for Cardiovascular Disease ModelingR01HL113006 · NHLBI · STANFORD UNIVERSITY · PI WU, JOSEPH C. · 2012 to 2025
$6.8MGenome Editing of Human iPSCs to Study Inherited Hypertrophic CardiomyopathyR01HL126527 · NHLBI · STANFORD UNIVERSITY · PI QI, LEI STANLEY, WU, JOSEPH C. · 2015 to 2022
$5.4MPrecision Targeting of Aldehyde Pathways for Patients Requiring AnesthesiaR35GM119522 · NIGMS · STANFORD UNIVERSITY · PI Eric Richard Gross · 2016 to 2026
$5.1MHuman iPSC Model to Elucidate Metabolic Interplay in Diabetic CardimyopathyR01HL146690 · NHLBI · STANFORD UNIVERSITY · PI LIAO, RONGLIH, MERCOLA, MARK · 2019 to 2025
$5.1MDelineating the Genetic Susceptibility of Smoking-Induced Vascular DysfunctionR00HL150319 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI GUO, HONGCHAO · 2023 to 2025
$747kIdentifying Angiocrine Factors for Cardiomyocyte Maturation Using Single-Cell SequencingK99HL150216 · NHLBI · STANFORD UNIVERSITY · PI PAIK, DAVID T · 2020 to 2021
$325kDelineating the Genetic Susceptibility of Smoking-Induced Vascular DysfunctionK99HL150319 · NHLBI · STANFORD UNIVERSITY · PI GUO, HONGCHAO · 2020 to 2021
$283kNHLBI NIH HHS K99 HL150216NHLBI NIH HHS K99 HL150319NHLBI NIH HHS P01 HL141084NHLBI NIH HHS R00 HL150319NHLBI NIH HHS R01 HL113006NHLBI NIH HHS R01 HL126527NHLBI NIH HHS R01 HL130020NHLBI NIH HHS R01 HL146690NIAAA NIH HHS R01 AA011147NIGMS NIH HHS R35 GM119522
Abstract
The common aldehyde dehydrogenase 2 (
Indexed as
Coronary Artery DiseaseInduced Pluripotent Stem CellsSodium-Glucose Transporter 2 InhibitorsAldehyde DehydrogenaseAldehyde Dehydrogenase, MitochondrialAnimalsBenzhydryl CompoundsGenome-Wide Association StudyGlucosidesHumansMiceAldehyde DehydrogenaseAldehyde Dehydrogenase, MitochondrialALDH2 protein, humanALDH2 protein, mouseBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.